Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

Running, not enrolling · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Breast Cancer

In brief

Explore the relationship between drug target ER gene single nucleotide polymorphisms and Raloxifene therapeutic effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target UGT gene single nucleotide polymorphisms and Raloxifene side-effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes.

Key facts

Study ID
NCT06062810
Run by
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
People needed
600
Starts
2025-06-21
Expected to finish
2026-12-28
Last updated by the study team
2026-04-23

Who can join

Age: 24 and older, up to 64. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.